Apollomics (APLM) Stock Price, News & Analysis

Company Overview

Apollomics, Inc., a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe. The company maintains its corporate headquarters in Palo Alto, while its R&D operations and clinical trial management span multiple sites in Shanghai and other major biotech hubs, reflecting its commitment to accelerating global development timelines and regulatory filings.

Apollomics is led by a management team with deep expertise in oncology drug discovery, clinical development and regulatory affairs. In addition to its internal pipeline, the company pursues strategic partnerships and licensing agreements to enhance its product portfolio and expand market access. Trading publicly on the Nasdaq Global Market under the ticker symbol APLM, Apollomics continues to advance its mission of delivering novel cancer therapies to patients worldwide.

Key Stats

• Today's Range: $13.53 to $13.85
• 50-Day Range: $12.95 to $20.39
• 52-Week Range: $3.66 to $42.12
• Volume: 1,137 shs
• Average Volume: 5,829 shs
• Market Capitalization: $29.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Apollomics Stock Analysis - MarketRank™

Apollomics scored higher than 16% of companies evaluated by MarketBeat, and ranked 804th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Apollomics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Apollomics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.12% of the float of Apollomics has been sold short.

Short Interest Ratio / Days to Cover

Apollomics has a short interest ratio ("days to cover") of 0.63, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apollomics has recently decreased by 55.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apollomics does not currently pay a dividend.

Dividend Growth

Apollomics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Apollomics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Apollomics insiders have not sold or bought any company stock.

Percentage Held by Institutions

19.13% of the stock of Apollomics is held by institutions.

Company Calendar

• Today: 5/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APLM
• CIK: 1944885
• Web: www.apollomicsinc.com
• Phone: 886-2-7713-7952
• Fax: 650-288-1674
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.96
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $8.50 million
• Price / Sales: 3.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.89) per share
• Price / Book: -4.68

Miscellaneous

• Outstanding Shares: 2,200,000
• Free Float: N/A
• Market Cap: $29.76 million
• Optionable: Not Optionable
• Beta: 1.53